DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2026)

Migraine | Emerging Therapies | Special Topics (US): CGRP-Targeted Therapies for the Treatment of Migraine

Migraine | Emerging Therapies | Special Topics (US): CGRP-Targeted Therapies for the Treatment of Migraine

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The migraine market stands on the verge of a renaissance; new and exciting therapies targeting the CGRP peptide could reach the market beginning in 2018. Two broad types of approaches are in final stages of development: monoclonal antibodies (MAbs) against CGRP or the CGRP receptor, and oral inhibitors of the CGRP receptor. Teva, Lilly, Alder, Amgen, and Novartis are developing MAbs for the prophylactic treatment of migraine; meanwhile, Allergan and Merck are developing oral inhibitors against the CGRP receptor for the preventative and acute treatment of migraine. With the imminent release of Phase III data and unique value propositions, how will neurologists view and incorporate an array of CGRP-targeted therapies? How would these compete with the numerous generics on the market and Botox?

QUESTIONS ANSWERED

  • How will migraine prophylaxis change with the launch of the CGRP-targeted therapies? In which lines of therapy and patient types do neurologists anticipate using these agents?
  • How might neurologists use anti-CGRPMAbs versus oral inhibitors in the migraine prophylaxis treatment algorithm? What are neurologists’ views of the two therapeutic approaches?
  • Which of the CGRP-targeted MAbs do surveyed physicians find most promising? How do surveyed neurologists believe these agents compare with Botox, and how will Botox use change?
  • What are neurologists’ views on oral CGRP antagonists in development? How burdensome do surveyed neurologists expect prescribing restrictions on these agents to be?

PRODUCT DESCRIPTION
Special Topics: Primary market research studies providing physician insights on trends and events affecting the broader industry to help you better anticipate your competitive position.

Table of contents

  • Special Topics (US): CGRP-Targeted Therapies for the Treatment of Migraine
    • Executive Summary
      • Background
      • Key Findings
    • Migraine Prophylaxis Today: Key Points, Factors, and Considerations
    • Anti-CGRP Monoclonal Antibodies
      • Anti-CGRP MAb Profiles
      • Physician Perceptions
        • Selecting Among Anti-CGRP MAbs
        • Neurologists' Preference Among Late-Phase Anti-CGRP MAbs
        • Neurologist Perceptions on Various Clinical and Nonclinical Treatment Attributes
      • Anticipated Use
        • Anticipated Use of Anti-CGRP MAbs in the Migraine Prophylaxis Treatment Algorithm
        • Anticipated Changes in Medical Practice Following the Launch of Anti-CGRP MAbs
      • Neurologists' Feedback on Delivery as a Driver
    • Oral CGRP Antagonists
    • Anti-CGRP MAbs and Cluster Headache
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Bibliography

Already a Client? Log in to access this report.

  • Pub Date: October 2017
  • Author(s): Angela Sparrow, PhD
  • Angela Sparrow provides expert insight and authors primary market research and forecasting content as a member of the Central Nervous System and Ophthalmology Team. During her time with the company, Angela has extensively covered migraine, contributing to numerous reports while staying up-to-date on the latest trends and news. Additionally, she provides detailed responses to client inquiries and has authored content focused on psychiatric indications, including opioid addiction and depression, as well as neuropathic pain. Dr. Sparrow holds a in behavioral neuroscience from the University of North Carolina at Chapel Hill and a Bachelor’s degree from Northeastern University. Before joining DRG, she was a postdoctoral fellow at McLean Hospital, Harvard Medical School, studying the role of kappa opioid receptors in addiction and withdrawal-induced depression.

Purchase Report

Recent reports:
You may also be interested in: